Medical Advocates
Etravirine (Intelence/TMC125)
  Conference Citations
XX International AIDS Conference
 XIX International AIDS Conference
 6th IAS Conference
XVIII International AIDS Conference
 12th European AIDS Conference
 5th IAS Conference
 Ninth Int Congress on Drug Therapy in HIV Infection
 48th ICAAC/46th IDSA
 XVII International AIDS Conference
 Conference Archives 		 
Etravirine Main Page Main New/Newsworthy  Home Page      
Last Update:  December 06, 2014 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
XX International AIDS Conference
     
XIX International AIDS Conference
     
  • Efficacy and impact on lipid parameters after switching to etravirine in HIV-positive patients with intolerance to suppressive HAART
    J.L. Casado, I. de Los Santos, M. del Palacio, et al
     Abstract
  • Outcomes of third-line antiretroviral therapy containing darunavir, etravirine or raltegravir in Thai children with HIV infection
    J. Ananworanich,, W. Prasitsuebsai, P. Kosalaraksa, et al
     Abstract
  • Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results
    G. Tudor-Williams, P. Cahn, K. Chokephaibulkit
     Abstract
  • Rilpivirine and etravirine resistance among HIV-1 subtype C infected children failing non-nucleoside reverse transcriptase inhibitor-based regimens in south India
         S. Saravanan, M. Vidya, R. Kanto
     Abstract
  • Cross-resistance among non-nucleoside reverse transcriptase inhibitors (NNRTIS): genotypic evaluation of the sensitivity to etravirine (ETR)
    in HIV-1-positive patients following failure to ‘first line ‘ treatmentsbased on nevirapine (NVP) and/or efavirenz
    A. Cudola1, S. Kademian2, M.G. Barbas2, J.F. De Leon3
     Abstract
6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • A WEEK-IN-REVIEW FEATURED REPORT
    POSTER
         Experience with non nucleoside reverse transcriptase inhibitors (NNRTIs): failure, resistance and susceptibility
    to etravirine
    T. Franic, D. Quan, A. Gowers, et al
    Poster         Abstract  
  • POSTER
     Persistence of antiretroviral regimens including raltegravir, maraviroc, darunavir and/or etravirine in clinical practice
    I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
         Poster     Abstract  
  • POSTER
     Experience with non nucleoside reverse transcriptase inhibitors (NNRTIs): failure, resistance and susceptibility to
    etravirine
    T. Franic, D. Quan, A. Gowers,  et al
         Poster     Abstract 
  • The SENSE trial: final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients
    J. Rockstroh, A. Streinu-Cerce, V. Pokrovsky, et al
     Abstract
  • Bioavailability of etravirine 200mg administered as a single 200-mg tablet versus two 100-mg tablets in HIV-negative,
    healthy volunteers
    T. Kakuda, G. de Smedt, R. Leemans, et al
     Abstract
  • Etravirine penetration in cervicovaginal compartment exceed the median inhibitory concentration in HIV-1
    infected women treated with etravirine-containing regimen (DIVA-02 study)
    C. Clavel, G. Peytavin, R. Tubiana, et al
     Abstract
  • Population pharmacokinetics of etravirine in HIV-1-infected treatment-experienced children and adolescents
    (6-17 years): week 24 primary analysis of the phase II PIANO trial
    T. Kakuda, B. Green, G. Morrish, et al
     Abstract
  • Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6-17 years):
    week 24 primary analysis of the phase II PIANO study
    G. Tudor-Williams, P. Cahn, K. Chokephaibulkit, et al
     Abstract
  • Etravirine resistance mutations among HIV-1 infected patients failing first and second line treatment in Malian
    cohort in West Africa
    A.I. Maiga, D.B. Fofana, M. Cissé, et al
     Abstract
XVIII International AIDS Conference
 
  • POSTER
     Drug-resistant genotyping to guide selection of etravirine, darunavir and raltegravir in salvage therapy
    for multi-drug-resistant cases improves outcomes
    N. Miyazaki, S. Matsushita, T. Fujii, et al
    PDF Poster         Abstract
  • POSTER
         Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in
    clinical practice
    I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
    PDF Poster        Abstract
  • POSTER
     Efficacy, safety and tolerability of etravirine (ETR) as salvage therapy in HIV-1-infected paediatric
    patients in clinical practice
    V. Briz, C. Palladino, M.L. Navarro, et al
    PDF Poster        Abstract
  • A phase IV, double blind, multi centre, randomised, placebo controlled, pilot study to assess the
    feasibility of switching individuals receiving efavirenz (EFV) with continuing central nervous system (
    CNS) adverse events (AE) to etravirine (ETR)
    L. Waters, M. Fisher, A. Winston, et al
     Abstract
  • Genotypic resistance to darunavir, tipranavir and etravirine in patients with failure to two or more
    ARV combinations in Mexico
    E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al
     Abstract
  • "Switch-EE": randomized double-blind cross-over comparison of etravirine and efavirenz – final
    per-protocol analysis from the Swiss HIV cohort (SHCS)
    A. Nguyen, A. Calmy, B. Hirschel1, et al
     Abstract
  • The SENSE trial: etravirine (ETR) shows fewer neuropsychiatric adverse events than efavirenz (EFV) i
    n treatment-naïve HIV-1 infected patients
    B. Gazzard, G. Di Perri, H. Furrer, et al
     Abstract
12th European AIDS Conference
 

  • A WEEK-IN-REVIEW FEATURED REPORT
    POSTER
         Etravirine demonstrates a favourable safety and tolerability profile:pooled 96-week results from t
    he Phase III DUET trials
    P-M Girard, B Grinsztejn, A Rachline, et al|
     PDF Poster

  • PDF POSTER
         Safety and pharmacokinetics of etravirine in pregnant HIV-infected women
    P Izurieta, TN akuda, A Clark, et al
     PDF Poster
  • POSTER
         Pharmacokinetic interaction between etravirine and lopinavir/ritonavir in HIV-negative volunteers
    M Schöller-Gyüre, TN Kakuda, James Witek, et al
     PDF Poster
  • A WEEK-IN-REVIEW FEATURED REPORT
    POSTER
         Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection:
    Week 96 analysis from the DUET trials
    B Clotet, C Katlama, N Clumeck, et al
     PDF Poster
  • POSTER
         The economic impact of national particularities in the healthcare system – calculation for hospital-related costs from
    pooled DUET trials by German diagnosis-related groups
    M Stoll ,V Donatz, C Corbett, S Martin
     PDF Poster
  • POSTER
         Cost-effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the German setting
    L Annemans, A Hill, E Smets, S Martin
     PDF Poster
5th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • A WEEK-IN-REVIEW-FEATURED REPORT
    POSTER
         Etravirine (ETR; TMC125) demonstrates durable efficacy in treatment-experienced
    patients in the DUET trials: pooled 96-week results
    A. Mills, P. Cahn, J.-M. Molina, et al
     PDF Poster         Abstract
  • POSTER
         Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients:
    pooled 96-week results from the phase III DUET trials
    T. Campbell, B. Grinsztejn, J. Hartikainen, et al
     PDF Poster         Abstract
  • POSTER
         Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected
    patients: pooled 96-week results from the phase III DUET trials
    J. Eron, R. Haubrich, P. Reiss, et al
    PDF Poster         Abstract
  • POSTER
         Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary
    to nonnucleoside reverse transcriptase inhibitor resistance
    E. Cordova, H. Mingrone, N. Porteiro, E. Loiza
    PDF Poster         Abstract
  • Is there any potential for first line etravirine use? Analysis from a large dataset of ART-naïve
    HIV infected patients undergoing resistance test
    M. Zaccarelli, A. Antinori, A. Cozzi-Lepri, et al
     Abstract
  • Virological efficacy of etravirine in multifailed patients: role of mutation score
    S. Lo Caputo, A. Di Biagio, P. Meraviglia, et al
     Abstract
  • Early detection of virologic failure is associated with preserved etravirine activity
    B. Taiwo, J. Idoko, S. Penugonda, et al
     Abstract
16th Conference on Retroviruses and Opportunistic
Infections
Ninth International Congress on Drug Therapy in HIV Infection
 
48th ICAAC/46th IDSA
 
XVII International AIDS Conference
 
2008 International HIV Drug Resistance Workshop
 
ISHEID 2008
 
17th Canadian Conference on HIV/AIDS Research
 
9th International Workshop on Clinical Pharmacology of HIV
 
6th European HIV Drug Resistance Workshop
 
HEP DART 2007
 
11th European AIDS Conference
 
IDSA 2007
 

Etravirine Main Page Main New/Newsworthy  Home Page      

Etravirine Conference Citations